News | June 21, 2011

New Molecular Imaging Agent Targets Cancerous Tumor Angiogenesis

June 21, 2011 – A study introduced at the Society of Nuclear Medicine’s (SNM) 58th Annual Meeting may lead to the next wave of cancer imaging by helping to develop a molecular imaging agent that detects many malignant cancers’ incessant development of blood vessels — a process called angiogenesis. A protein biomarker known as CD105 has been shown to indicate tumor angiogenesis in cancer patients.

“Noninvasive molecular imaging is a critical component of 21st century personalized medicine, and one of the hallmarks of cancer is angiogenesis,” says Weibo Cai, Ph.D., assistant professor of radiology, medical physics and biomedical engineering at the University of Wisconsin–Madison’s School of Medicine and Public Health. “CD105 is considered by many to be the best biomarker for evaluating tumor angiogenesis. Noninvasive imaging of this protein’s expression could potentially play a variety of roles in the future of cancer patient management. CD105-targeted imaging agents also represent a new paradigm for the assessment of cancer therapies that target tumor angiogenesis. Applications for this agent could reach far beyond cancer and open many new avenues for future research.”

Malignant cancers are defined by their ability to grow like weeds, forming fast and strong networks of blood vessels that carry oxygen and nutrients to the cancer’s insatiable cellular structure. Endoglin, or CD105, is a naturally occurring protein that resides on the cell’s surface. Above-normal expression of this protein is associated with poor cancer prognosis in more than 10 solid tumor types. The clinical standard for evaluating tumor angiogenesis is microvessel density (MVD) analysis, which is conducted by staining CD105 in tumor tissues that have been obtained by either surgical removal or biopsy. This study represents the first of its kind to report preliminary data on the noninvasive imaging of CD105 expression with positron emission tomography (PET), which provides a reliable measure of angiogenesis in the tumor.

Researchers used the medical isotope Copper-64 (Cu64) to label an antibody called TRC105, which binds to CD105. The full name of the agent is (64)Cu-DOTA-TRC105. The TRC105 antibody is currently being studied in a U.S. multicenter phase 1 human trial, and multiple phase 2 therapy trials are planned or already underway for a range of cancer types. The current study specifically marks the effectiveness of using 64Cu-DOTA-TRC105 to gauge tumor angiogenesis. Results of the study showed this PET imaging agent to be highly effective, with rapid and persistent CD105-targeted uptake by tumors in mice.

Not only could this potentially be a turning point for cancer imaging and therapy, but some other major causes of death like heart attack, stroke and atherosclerosis also actively demonstrate the over-expression of CD105. Molecular imaging of this protein could one day lead to expanded tools for the detection and treatment of any number of diseases characterized by enhanced angiogenesis.

Scientific Paper 296: Y. Zhang, H. Hong, Y. Yang, J. Engle, T. Barnhart, R. Nickles, B. Leigh, W. Cai, University of Wisconsin Madison, Madison, Wis.; Tracon Pharmaceuticals Inc., San Diego, Calif.; “Positron emission tomography imaging of CD105 expression during tumor angiogenesis.” SNM’s 58th Annual Meeting, June 4–8, 2010, San Antonio, Texas

For more information: www.snm.org

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.